SCHEMBL4576855

SCHEMBL4576855

O=C(CCl)Nc1ccc2c(c1)NC(=O)CO2

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.62
▸ MAPT P10636 4/20 0.62
▸ KMT2A Q03164 3/20 0.60
▸ HTT P42858 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ LMNA P02545 1/20 0.56
▸ MEN1 O00255 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ TRPV1 Q8NER1 10/20 0.53
▸ POLB P06746 1/20 0.53
▸ GAA P10253 1/20 0.52
▸ THRB P10828 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4577333 0.90 ALDH1A1 (0.57) ALDH1A1MAPTKMT2AHTTSMN1; SMN2
SCHEMBL27652513 0.87 MAPT (0.62) ALDH1A1MAPTKMT2ALMNAMEN1
SCHEMBL14073095 0.85 MAPT (0.60) ALDH1A1MAPTKMT2ALMNAMEN1
SCHEMBL14073612 0.83 MAPT (0.58) ALDH1A1MAPTKMT2ALMNAMEN1
SCHEMBL14073622 0.81 POLB (0.59) ALDH1A1MAPTKMT2ALMNATRPV1
SCHEMBL8192718 0.80 ALDH1A1 (0.77) ALDH1A1MAPTKMT2ALMNATRPV1
SCHEMBL14073519 0.80 KMT2A (0.55) ALDH1A1MAPTKMT2AHTTSMN1; SMN2
SCHEMBL14073688 0.79 PARP1 (0.54) ALDH1A1MAPTKMT2ALMNACYP1A2
SCHEMBL27981766 0.79 MAPT (0.62) ALDH1A1MAPTKMT2ALMNAMEN1
SCHEMBL3588732 0.79 MAPT (0.62) ALDH1A1MAPTKMT2AMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7435744-B2 Piperidine derivatives as NMDA receptor antagonists GEDEON RICHTER VEGYESZETI GYAR RT (HU) 2008-10-14 — — US disclosed
CN-100413860-C piperidine derivatives as NMDA receptor antagonists HUNGARY GIREL GYOGYSZERGYAR (HU) 2008-08-27 — — CN disclosed
CN-1556805-A piperidine derivatives as NMDA receptor antagonists ������ҩ�����޹�˾ 2004-12-22 — — CN disclosed
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists UCB Biopharma SRL (BE) 2004-08-12 — — US disclosed
EP-1409477-A1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2004-04-21 — — EP disclosed
WO-2003010159-A1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2003-02-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists GRIN1, GRIN2D, GRIN2C ALDH1A1 1856/4885MAPT 3836/4885KMT2A 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback